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PathogenesisThe complement system functions as an immune surveillance system that rapidly responds to infection.
Activation of the complement system by speciﬁc recognition pathways triggers a protease cascade, generating
cleavage products that function to eliminate pathogens, regulate inﬂammatory responses, and shape adaptive
immune responses. However, when dysregulated, these powerful functions can become destructive and the
complement system has been implicated as a pathogenic effector in numerous diseases, including infectious
diseases. This review highlights recent discoveries that have identiﬁed critical roles for the complement
system in the pathogenesis of viral infection.ology, University of Colorado
8333, Aurora, CO 80045, USA.
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The complement system is a major component of innate immunity
and consists of both soluble factors and cell surface receptors that
interact to sense and respond to invading pathogens. The complement
system links the innate and adaptive immune responses by a varietyof mechanisms including enhancing humoral immunity, regulating
antibody effector mechanisms, and modulating T cell function
(Carroll, 2004). In addition to these roles in normal host immune
responses, the complement system has pathogenic roles in a variety of
ischemic, inﬂammatory, and autoimmune diseases (Holers, 2003).
The activation and regulation of the complement system are
described in a number of recent excellent review articles (Gros et al.,
2008; Ricklin et al., 2010; Zipfel and Skerka, 2009). In brief, threegeneral
activation pathways, referred to as the classical, alternative, and lectin
pathways, converge on C3, the central component of the complement
system (Fig. 1). In addition, novel complement activation pathways
Fig. 1. Schematic of the complement system. Complement is activated by threemajor pathways. The classical pathway is primarily activated when C1q interacts with IgM and certain
IgG isotypes bound to antigen. C1q-associated C1s cleaves C4 and C2 to form the classical pathway (CP) C3 convertase (C4bC2a). The lectin pathway (LP) is initiated by carbohydrate
pattern recognition receptors such as mannose-binding lectin (MBL) and the ﬁcolins (F) which are in a complex with enzymes known as MBL-associated serine proteases (MASPs).
MASP-2 activates the complement system by cleaving both C4 and C2 to form the C4bC2a C3 convertase. The alternative pathway (AP) is activated by spontaneous hydrolysis of C3
(C3-H2O). This pathway also functions as an ampliﬁcation loop for the cleavage of C3 initially triggered by other mechanisms. C3-H2O or C3b bound to target surfaces are bound by
the protease factor B (fB). Factor D (fD) is a serine protease that cleaves C3-H2O or C3b-bound fB, resulting in the generation of Bb and formation of the alternative pathway C3
convertase (C3bBb). Both the classical and alternative convertases function to cleave C3 to C3a and C3b. Cleavage of C3 exposes a reactive thioester bond in C3b that allows for the
covalent attachment of C3b to target surfaces. In addition, C3b can bind to either the classical or alternative C3 convertases resulting in a change of the substrate speciﬁcity of the
convertases from C3 to C5. These C5 convertases cleave C5 to C5a and C5b. Release of C5b promotes assembly of the C5b–C9membrane attack complex (MAC) which can directly lyse
pathogens or pathogen-infected cells. C3b is further cleaved by factor I (fI), a function enhanced by factor H (fH), to generate degradation products such as iC3b and C3dg. C3b and its
degradation products interact with cellular receptors to regulate effector functions such as phagocytosis and B cell activation. The anaphylatoxins C3a and C5a interact with speciﬁc
receptors to promote chemotaxis and regulate effector functions of cells of both the innate and adaptive immune response.
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SIGN-R1 expressed onmacrophages (Kang et al., 2006), C5 activation by
thrombin (Huber-Lang et al., 2006), and the properdin-activated
pathway (Kemper et al., 2010). The classical pathway is primarily
activated by IgM and certain IgG isotypes bound to antigen. These
immune complexes interactwith the complement component C1q. C1q
binding leads to the activation of two serine proteases associated with
C1q, C1r and C1s. C1s cleaves C4 into C4a and C4b resulting in the
exposure of a reactive thioester that allows covalent attachment of C4b
on surfaces. C2 binds C4b and is also cleaved by C1s to form the classical
pathway C3 convertase (C4bC2a). C3 convertases cleave C3 to amplify
complementactivation and lead to the generation of ligands for a variety
of complement receptors. The lectin pathway is initiated by pattern
recognition receptors such as mannose-binding lectin (MBL) and the
ﬁcolins (Fig. 1). MBL and ﬁcolins contain carbohydrate-recognition
domains that recognize carbohydrate patterns on the surfaces of cells or
invading microorganisms. MBL and the ﬁcolins are in a complex with
enzymes knownasMBL-associated serine proteases (MASPs). Similar to
C1s, MASP-2 activates the complement system by cleaving both C4 and
C2 to form the C4bC2a C3 convertase. The alternative pathway is
activated by spontaneous hydrolysis of C3 (C3-H2O) (Fig. 1). This
pathway also functions as an ampliﬁcation loop for the cleavage of
C3 initially triggered by other mechanisms. C3-H2O or C3b bound to
target surfaces are bound by the protease factor B (fB). Factor D (fD) is a
serine protease that cleaves C3-H2O or C3b-bound fB, resulting in the
generation of Bb and formation of the alternative pathway
C3 convertase (C3bBb). Both the classical and alternative convertases
function to cleave C3 to C3a and C3b. Similar to C4, cleavage of
C3 exposes a reactive thioester bond in C3b that allows for the covalent
attachment of C3b to target surfaces. In addition, C3b can bind to eitherthe classical or alternative C3 convertases resulting in a change of the
substrate speciﬁcity of the convertases from C3 to C5. These
C5 convertases cleave C5 to C5a and C5b. Release of C5b promotes
assembly of the C5b–C9 membrane attack complex (MAC) which can
directly lyse pathogens or pathogen-infected cells. The anaphylatoxins
C3a and C5a interact with speciﬁc receptors to promote chemotaxis and
regulate effector functions of cells of both the innate and adaptive
immune response.
A variety of soluble and membrane-associated proteins regulate
complement activation. Factor H (fH), C4b-binding protein (C4BP),
and C1 inhibitor (C1-INH) are soluble proteins that regulate activation
of the complement system. fH promotes the dissociation of C3bBb
convertases and acts as a cofactor for factor I (fI)-mediated cleavage of
C3b. C4BP functions similar to fH in that it promotes dissociation of
C4bC2a convertases and acts as a cofactor for fI-mediated cleavage of
C4b. The C1-INH is a serine protease inhibitor that inactivates both the
C1q-associated proteases of the classical pathway (C1r and C1s) as
well as the MASPs of the lectin pathway. Membrane-associated
regulators of complement activation include decay accelerating factor
(DAF/CD55), membrane cofactor protein (MCP/CD46), complement
receptor 1 (CR1/CD35), CD59, and Crry (rodent-speciﬁc). These
proteins function to destabilize both the classical and alternative
complement convertases, act as cofactors for fI-mediated cleavage of
C3b and C4b, and prevent assembly of the MAC on cell surfaces.
The complement system is increasingly recognized as a mediator
of protection or pathology in a variety of viral infections. Furthermore,
the continued identiﬁcation of novel mechanisms of viral antagonism
of complement highlight the important role this system has in viral
pathogenesis. Here, we review recent studies of viral interactions with
a variety of components of the complement system and emphasize
364 K.A. Stoermer, T.E. Morrison / Virology 411 (2011) 362–373those ﬁndings that describe how these interactions impact the
development of virus-induced disease.
Viral evasion of the complement system
Perhaps the best evidence that complement has an important role
in the outcome of virus infection is the identiﬁcation of speciﬁc
mechanisms evolved by viruses to evade the complement system
(Fig. 2). One mechanism employed by viruses is to directly encode
proteins that have structural and functional homology to host proteinsFig. 2. Examples of viral evasion of the complement system. A.) Virally encoded proteins allo
protein (CP) binds MBL and C1q, inhibiting the activation of both the lectin and classical path
(NS1) binds C4 and C1s, leading to enhanced cleavage of C4 to C4b, as well as factor H (fH), l
iC3b. Additionally, membrane-bound ﬂavivirus NS1 decreases deposition of C3b and the MA
protein (RCA) blocks C3 deposition, whereas the HSV-1 glycoprotein (gC) binds C3b and bl
enzymes (SPICE), the vaccinia virus complement control protein (VCP), the monkeypox vi
complement enzymes (EMICE) function as cofactors for fI-mediated cleavage of C3b by bin
complement cascade in parentheses, are indicated in red. B.) Some viruses recruit host compl
human T-lymphotropic virus-1 (HTLV-1), and human cytomegalovirus (HCMV) incorporat
simian virus 5 (SV5) and mumps virus (MuV) recruit CD46/MCP into their virions. Physiolog
regulatory proteins into their virions are indicated in red.that function as regulators of complement activation. Gammaherpes-
viruses, including Kaposi's sarcoma-associated herpesvirus, herpesvi-
rus saimiri, and murine γ-herpesvirus 68 (γHV68) encode homologs
of complement regulatory proteins (Albrecht and Fleckenstein, 1992;
Mullick et al., 2003a; Spiller et al., 2003; Virgin et al., 1997). TheγHV68
regulator of complement activation (RCA) protein is expressed on the
surfaces of infected cells and is detected in supernatants of γHV68-
infected cells, thus it has bothmembrane-associated and soluble forms
(Kapadia et al., 1999). Recombinant γHV68 RCA protein and super-
natants from γHV68-infected cells blocked C3 deposition on zymosanw viruses to evade complement-mediated destruction. Human astrovirus (HastV) coat
ways. Inﬂuenza Amatrix (M1) protein also binds C1q. Flavivirus nonstructural protein 1
eading to increased cofactor activity of fH for factor I (fI)-mediated cleavage of C3b into
C on cell surfaces. The murine gammaherpesvirus-68 (γHV68) regulator of complement
ocks the binding of properdin and C5 to C3b. The variola virus inhibitor of complement
rus inhibitor of complement enzymes (MOPICE), and the ectromelia virus inhibitor of
ding to C3b and C4b. Viruses, with their corresponding proteins that interfere with the
ement regulatory proteins into their virions. Human immunodeﬁciency virus-1 (HIV-1),
e the host complement control proteins CD55/DAF and CD59 into their virions, while
ical complement regulatory proteins are shown in green. Viruses that incorporate these
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(Kapadia et al., 1999). To directly test the role of the γHV68 RCA
protein in pathogenesis, Kapadia et al. generated a γHV68 deleted for
the RCA protein and evaluated the outcome of infection in both wild-
type and C3-deﬁcient mice (Kapadia et al., 2002). Deletion of the
γHV68 RCA protein resulted in decreased virulence following
intracranial inoculation of weanling mice or intraperitoneal inocula-
tion of adult IFN-γ−/− mice, models of acute γHV68-induced
meningoencephalitis and γHV68 persistent infection, respectively.
Genetic deletion of C3 in the host was able to restore virulence of the
RCA protein-deleted virus in the model of acute meningoencephalitis
and enhanced its persistent replication, conﬁrming that RCA protein
interaction with the host complement system is a critical regulator of
γHV68 pathogenesis. Interestingly, although wild-type mice had a
reduced number of latently infected cells compared to C3−/− mice,
indicating that complement regulates the establishment of γHV68
latent infection, this effect was not counteracted by the γHV68 RCA
protein (Kapadia et al., 2002).
Poxviruses, such as variola virus, vaccinia virus, monkeypox virus,
and ectromelia virus, also encode complement regulatory proteins
that have structural and functional homology to host encoded
regulators of the complement pathway (Mullick et al., 2003b)
(Fig. 2A). The variola virus inhibitor of complement enzymes
(SPICE), the vaccinia virus complement control protein (VCP), the
monkeypox virus inhibitor of complement enzymes (MOPICE), and
the ectromelia virus inhibitor of complement enzymes (EMICE) all
bind to C3b, as well as C4b, and function as cofactors for fI-mediated
cleavage of C3b (Liszewski et al., 2006;Moulton et al., 2010; Rosengard
et al., 2002; Sahu et al., 1998). A VCP-deleted vaccinia virus produced
smaller skin lesions in rabbits compared to wild-type vaccinia virus
(Isaacs et al., 1992) and pathogenesis studies in cynomolgus monkeys
with different strains of monkeypox virus revealed that MOPICE is
deleted from the less virulent strains (Chen et al., 2005). Furthermore,
SPICE is a much more potent inhibitor of human complement
compared to VCP and MOPICE, correlating with the increased
virulence of variola virus in humans compared to vaccinia virus and
monkeypox virus (Liszewski et al., 2006; Rosengard et al., 2002).
Taken together, these studies and the ﬁndings that multiple compo-
nents of the complement pathway are required for mice to survive
ectromelia virus infection (discussed below), indicate that comple-
ment activation and viral evasion of the complement system are
critical determinants of poxvirus pathogenesis.
In contrast to herpesviruses and poxviruses, ﬂaviviruses encode a
protein that antagonizes the complement system despite the lack of
any sequence homology to known regulators of the complement
system. The nonstructural protein 1 (NS1) encoded by ﬂaviviruses is a
glycosylated protein detected within infected cells, on cell surfaces,
and secreted from infected cells (Alcon-LePoder et al., 2006). NS1
accumulates in the serum of dengue virus-infected individuals and
high circulating levels are associated with severe disease (Avirutnan
et al., 2006; Libraty et al., 2002). In an attempt to purify WNV NS1
from cell supernatants, Chung et al. observed that fH copuriﬁed with
NS1 (Chung et al., 2006). Soluble WNV NS1 was found to enhance
the cofactor activity of fH for fI-mediated cleavage of C3b to iC3b,
while cell surface-associated NS1 decreased deposition of C3b and the
C5b–C9 membrane attack complex on cell surfaces (Fig. 2A).
Flavivirus NS1 also binds to C4 and C1s (Avirutnan et al., 2010)
(Fig. 2A). These activities enhanced the cleavage of C4 to C4b and
resulted in reduced activity of the classical C3 convertase (C4b2a) and
reduced C4b and C3b deposition on cell surfaces (Avirutnan et al.,
2010), providing an additional mechanism by which ﬂaviviruses can
evade complement-dependent neutralization. Soluble NS1 has also
been reported to bind the complement inhibitory factor clusterin,
which normally inhibits the formation of the C5b–C9 membrane
attack complex (Kurosu et al., 2007), however, a functional conse-
quence of this interaction has not been reported.Many other viruses employ a similar complement evasion strategy
by encoding proteins that bind and inhibit or sequester complement
components. For example, the coat protein of human astrovirus type 1
(HAstV-1) suppresses complement activation by binding C1q,
functionally displacing the protease tetramer, and thus inhibiting
classical pathway activation (Bonaparte et al., 2008; Hair et al., 2010)
(Fig. 2A). This was further demonstrated for serotypes 2 and 4
(Bonaparte et al., 2008). The astrovirus coat protein also bound MBL
and inhibited mannan-mediated activation of the lectin pathway
(Hair et al., 2010). As discussed below, C1q enhances the neutralizing
and hemagglutination inhibition activity of anti-inﬂuenza antibodies.
Experimental evidence suggests that the matrix (M1) protein of
inﬂuenza A virus has evolved to counteract this host response, as M1
prevents complement-mediated neutralization of inﬂuenza virus in
vitro by binding C1q and blocking the interaction between C1q and
IgG (Zhang et al., 2009). Herpes simplex virus 1 (HSV-1) encodes
several immune modulators, including glycoprotein C (gC), which
inhibits activation of the complement cascade by binding C3 and C3
fragments (Friedman et al., 1984; Fries et al., 1986; Kostavasili et al.,
1997; Tal-Singer et al., 1991) and by blocking binding of properdin
and C5 to C3b (Fries et al., 1986; Hung et al., 1994; Kostavasili et al.,
1997). These effects are mediated by two distinct domains in gC: one
domain blocks properdin and C5 binding to C3b, and the other directly
binds C3 and C3 fragments (Hung et al., 1994). In vitro, gC protects
HSV-infected cells from complement-mediated lysis (Harris et al.,
1990) and cell-free virus from complement-mediated neutralization
(Friedman et al., 1996; Hidaka et al., 1991). It was further demon-
strated that natural IgM antibody binds and neutralizes HSV-1 and
HSV-2 gC-null viruses via a C1q-, C3-, and C5-dependent mechanism
(Hook et al., 2006). Studies in animal models have conﬁrmed the
importance of gC-mediated complement inhibition in HSV-1 patho-
genesis. When inoculated intravaginally into wild-type guinea pigs,
but not C3-deﬁcient guinea pigs, a gC-null HSV-1 replicated less
efﬁciently and caused signiﬁcantly less severe vaginitis compared to
wild-type HSV-1 (Lubinski et al., 1998). The C3-dependent attenuated
phenotype of gC-null HSV-1 was conﬁrmed by inoculating wild-type
and C3-deﬁcient mice via skin scratch and evaluating HSV-1-induced
zosteriform disease (Lubinski et al., 2002, 1998). Further studies with
this murine model demonstrated that both domains of gC that
modulate complement activation are critical virulence factors;
however, HSV-1 speciﬁcally lacking the C3 binding domain was
more attenuated compared to HSV-1 speciﬁcally lacking the C5/
properdin inhibitory domain (Lubinski et al., 1999). Importantly, the
gC mutant viruses were as virulent as wild-type virus in C3-deﬁcient
mice, indicating that the gC interactions with the complement system
regulate HSV-1 pathogenesis (Lubinski et al., 1999). Most recently, the
knowledge gained from these studies was utilized to improve vaccine
efﬁcacy against HSV-1 infection. Awasthi and colleagues demonstrat-
ed that combined immunizationwith theHSV-1 glycoproteinD (gD), a
potent immunogen, and gC prevented HSV-1 evasion from comple-
ment, due to the development of an anti-gC antibody response, and
enhanced the protection provided by gD immunization (Awasthi et al.,
2009).
A number of viruses evade the complement systemby recruiting host
complement regulatory proteins into their virions (Fig. 2B). For instance,
Human immunodeﬁciency virus-1 (HIV-1), human T-lymphotropic
virus-1 (HTLV-1), and human cytomegalovirus (HCMV) incorporate
the complement control proteins CD55/DAF and CD59 into their
virions, thus protecting virions from complement-mediated destruction
(Saifuddin et al., 1995; Spear et al., 1995). Simian virus 5 (SV5)
and mumps virus (MuV), both paramyxoviruses, can be neutralized in
a C3-dependent manner resulting in virion aggregation and virion lysis,
respectively (Johnson et al., 2008). Further studies revealed that both SV5
and MuV virions contained CD46/MCP, a membrane-associated protein
that has cofactor activity for fI-mediated cleavage of C3b and C4b. The
incorporation of CD46 into SV5 and MuV conferred virion-associated
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ment-dependent neutralization (Johnson et al., 2009). Thus, these
viruses have evolved to usurp host complement regulatory proteins to
avoid complement-mediated destruction.
Protective roles for complement during viral infections
Direct inactivation of virions by MBL
Mannose binding lectin (MBL) is a C-type lectin that plays an
important role in innate immunity by binding to carbohydrates on a
wide range of pathogens (Fujita, 2002). Recognition of carbohydrates
is mediated via a C-terminal carbohydrate recognition domain. Once
bound, MBL can activate complement, due to its association with
MASPs, or act directly as an opsonin. Polymorphisms in the promoter
and structural regions of the human MBL2 gene affect MBL oligomer
formation and circulating levels of the protein (Madsen et al., 1995).
Due to these different mutations, humans exhibit a 1000-fold
variation in circulating MBL levels that occur with varying frequencies
in different populations. Recently, a number of studies have
demonstrated that direct interactions between MBL and virus
particles can neutralize infection.
MBL has been found to bind directly to virions from a number of
different virus families, including human immunodeﬁciency virus
(HIV), severe acute respiratory syndrome coronavirus (SARS-CoV),
Ebola virus, dengue virus (DENV), andWest Nile virus (WNV) (Fig. 3).
The ﬁnding that the HIV envelope glycoprotein, gp120, is modiﬁed
with high mannose oligosaccharides led researchers to test the
potential of HIV and gp120 to function as ligands for MBL. MBL was
shown to bind directly to HIV-infected cells and recombinant gp120
(Ezekowitz et al., 1989). The importance of these interactions was
demonstrated by experiments showing MBL could inhibit infection of
speciﬁc target cells by cell culture-derived HIV. Although primary
isolates of HIV bound to MBL (Saifuddin et al., 2000), MBL binding
inefﬁciently inhibited infection of peripheral blood mononuclear cells
(Ying et al., 2004). However, MBL binding did lead to efﬁcient
opsonization and uptake of HIV by mononuclear phagocytes (Ying
et al., 2004). Despite these ﬁndings, the role of MBL in HIVFig. 3. Complement pathways that mediate protection and/or pathology in response to virus
identiﬁed to mediate protection (virus name or abbreviation in black) and/or pathology (v
severe acute respiratory syndrome coronavirus; WNV, West Nile virus; DENV, dengue virus;
lymphocytic choriomenigitis virus; RRV, Ross River virus; TMEV, Theiler's murine encephalpathogenesis is still unclear. Different studies investigating the
association between MBL levels and HIV infection have found no
association, increased susceptibility among individuals with low MBL
levels, and increased susceptibility among individuals with high MBL
levels (Ji et al., 2005a). However, this area of research has led to an
effort to identify lectins that interact with HIV and inhibit infection as
a novel therapeutic approach to prevent HIV infection and disease
(Alexandre et al., 2010; Hoorelbeke et al., 2010; Huskens et al., 2010).
MBL has also been reported to bind to SARS-CoV or retroviral
particles pseudotypedwith the SARS-CoV spike glycoprotein (SARS-S)
(Ip et al., 2005; Zhou et al., 2010) (Fig. 3). Similarly, MBL binds
efﬁciently to retroviral particles pseudotyped with Ebola virus or
Marburg virus glycoproteins (Ji et al., 2005a) (Fig. 3). Importantly, all
of these studies showed direct MBL-mediated neutralization of virus
infection (Ip et al., 2005; Ji et al., 2005b). MBL binding to SARS-S was
dependent on a single N-linked glycosylation site in SARS-S (N330)
(Zhou et al., 2010).MBLbinding blocked the interaction of SARS-Swith
DC-SIGN, previously identiﬁed to interact with SARS-S (Yang et al.,
2004), but not with the major SARS-CoV receptor angiotensin-
converting enzyme 2 (ACE2) (Li et al., 2003). Serum levels of MBL
were reported to be signiﬁcantly lower in patients with SARS than in
control patients; there was, however, no association between MBL
genotypes and mortality related to SARS (Ip et al., 2005). A second
study also reported that MBL gene polymorphisms associated with
reducedMBL levels were signiﬁcantly associatedwith susceptibility to
SARS-CoV infection (Zhang et al., 2005). However, a third study
reported that MBL genotypes and allele frequencies do not inﬂuence
the outcome of infection with SARS-CoV (Yuan et al., 2005).
Finally, studies showed that MBL binds N-linked glycans on the
structural proteins of WNV and DENV, resulting in neutralization
through a C3- and C4-dependent mechanism that occurred, in part, by
blocking viral fusion (Fuchs et al., 2010). These ﬁndings indicated that
MBL opsonization was not sufﬁcient for neutralization, but rather
deposition of C3 or C4 onto virions was also required. For WNV,
neutralization occurred only with virus produced in insect cells; for
DENV, neutralization occurred with insect and mammalian cell-
derived virus (Fuchs et al., 2010). Experiments in mice demonstratedinfections. Speciﬁc molecules and pathways in the complement system that have been
irus name or abbreviation in red) following infection with speciﬁc viruses. SARS-CoV,
VSV, vesicular stomatitis virus; HSV-1, Herpes simplex virus-1; FV, Friend virus; LCMV,
omyelitis virus; HCV, hepatitis C virus.
367K.A. Stoermer, T.E. Morrison / Virology 411 (2011) 362–373an accelerated intravascular clearance of DENV or of a WNV mutant
with two N-linked glycans on its E protein, but not wild-type WNV,
that was MBL-dependent (Fuchs et al., 2010).
Enhancement of humoral immunity to viruses
The complement system enhances humoral immunity by a
number of different mechanisms. Complement regulates effector
functions of both natural and immune antibodies, complement
component C3 and its receptors participate in the capture and
transport of antigen to the B cell compartments of secondary
lymphoid tissue (Gonzalez et al., 2010), and complement receptor 2
(CR2, CD21) and complement receptor 1 (CR1, CD35) expression by
follicular dendritic cells function to retain antigen in the lymphoid
follicles, which is required for the generation of a normal humoral
immune response (Fang et al., 1998). On B lymphocytes, CR2 forms a
complex with other proteins, such as CD19, to activate signal
transduction pathways that regulate B cell activation. Coligation of
the B cell receptor and CR2, which binds the cleavage products iC3b,
C3dg, and C3d covalently attached to antigen, lowers the threshold of
B cell activation (Bradbury et al., 1992; Hebell et al., 1991; Heyman et
al., 1990). In fact, linking C3d to a model antigen generated a fusion
protein that was 100–1000 fold more immunogenic (Dempsey et al.,
1996). Numerous studies have established a critical role for the
complement system in regulating humoral immunity to virus
infection. Below, we highlight recent ﬁndings with a particular
emphasis on studies that have investigated these pathways in the
context of viral pathogenesis.
Natural antibody and complement neutralize virus. The humoral
immunity of naïve individuals consists primarily of natural IgM
antibodies (Ochsenbein and Zinkernagel, 2000). Natural IgM is
polyreactive and it is thought that endogenous antigens drive the
generation of natural IgM. IgM, which exists in circulation primarily as
a pentamer, has a 1000-fold greater binding afﬁnity for C1q compared
with IgG, making it a potent activator of the complement system
(Ehrenstein and Notley, 2010).
Initial studies revealed the presence of natural IgM speciﬁc for
various viral pathogens, including lymphocytic choriomeningitis virus
(LCMV), vesicular stomatitis virus (VSV), and vaccinia virus (VV), in
the sera of naïve mice. By reconstituting RAG-1−/− mice with sera
from naïve mice, researchers demonstrated that natural antibodies
protectedmice from both VSV dissemination and disease (Ochsenbein
et al., 1999a). Earlier studies had shown that a natural IgM antibody to
a VSV antigen forms an immune complex that activates C1 and
initiates complement activation via the classical pathway at the viral
surface, thus neutralizing VSV (Beebe and Cooper, 1981). This
neutralization was associated with C3b deposition on the viral
envelope that likely interferes with VSV attachment to susceptible
cells. Natural IgM and components of the classical activation pathway
have also been shown to neutralize inﬂuenza virus (Jayasekera et al.,
2007). Interestingly, rather than resulting in lysis of virions, these
interactions resulted in coating and aggregation of virus particles. To
test the signiﬁcance of these interactions on inﬂuenza pathogenesis,
RAG-1−/− mice were reconstituted with natural IgM and then
challenged with the mouse-adapted PR8 strain of inﬂuenza. Recon-
stitution prolonged mouse survival following inﬂuenza challenge,
suggesting that natural IgM and complement also protect the host
from inﬂuenza infection. Furthermore, both complement and IgM
were required for the development of protective immunity against
inﬂuenza virus after immunization (Fernandez Gonzalez et al., 2008).
Similar to inﬂuenza virus, sera from naïve mice neutralizes
ectromelia virus by a mechanism dependent on both complement
and natural antibodies (Moulton et al., 2008). Further analyses
revealed that opsonization of ectromelia virus particles with C3b
and C4b was the primary mediator of neutralization. Consistent with
these ﬁndings, ectromelia virus dissemination was more efﬁcient andviral loads in tissues were greater in mice deﬁcient in C3. In mortality
studies, the genetic deﬁciency in the complement components C3, C4,
or fB resulted in a higher mortality rate compared to wild-type mice.
In addition, reconstitution of B cell-deﬁcient μMT mice with sera
containing natural antibodies signiﬁcantly increased survival follow-
ing inoculation of ectromelia virus. In sum, these studies have
revealed the important role of natural antibodies and complement
in protection from virus infection.
Complement-mediated enhancement of B lymphocyte responses protects
from virus-induced disease. The study of humoral responses to
herpesvirus infections has yielded important insights into comple-
ment-mediated regulation of B cell function. Mice deﬁcient in C3, C4,
or CR2 (which in mice encodes both CR1 and CR2) had signiﬁcantly
diminished IgG responses following Herpes Simplex virus-1 (HSV-1)
infection, suggesting that activation of the classical pathway plays a
key role in regulating the antibody response to HSV-1 infection (Da
Costa et al., 1999). Interestingly, C3-deﬁcient mice reconstituted with
bone marrow from wild-type mice developed normal antibody
responses following HSV-1 infection, while wild-type mice recon-
stituted with bone marrow from C3-deﬁcient mice had signiﬁcantly
diminished IgG responses (Verschoor et al., 2003, 2001). These
experiments indicated that C3 derived from bone marrow cells was
essential to enhance B cell activation in response to HSV-1 infection
and were some of the ﬁrst studies to describe an important function
for complement factors synthesized locally by a non-hepatic cellular
source.
In contrast to HSV-1 infection, IgG responses to VSV infection,
which is neurotropic in mice and can cause paralysis and death, were
similar in C3−/−mice compared to wild-type mice (Ochsenbein et al.,
1999b). Instead, researchers discovered that complement compo-
nents C3 and C4, but not CR2, were critical for initial anti-VSV IgM
responses. Further experiments suggested that complement was
critical for targeting VSV antigens to marginal zone macrophages in
lymphoid tissues to stimulate B cells and IgM production. C3−/−mice,
but not CR2−/− mice, were more susceptible to lethal VSV infection,
suggesting that the depressed IgM responses were critical to limit VSV
spread and replication in the central nervous system.
Unlike VSV infection, the genetic absence of C3 or CR2 resulted in
increased WNV-induced mortality, earlier WNV entry into the central
nervous system, and greater viral loads of WNV in the brains of mice,
suggesting complement-mediated regulation of B cell responses was
critical to control WNV dissemination, replication, and disease
(Mehlhop et al., 2005). In fact, C3 and CR1/CR2 were required for
normal anti-WNV IgM and IgG responses in mice and passive transfer
of immune serum protected C3−/−mice from lethalWNV infection. In
further studies, antibody responses to WNV were found to be normal
in mice deﬁcient in fB and fD, components of the alternative
complement activation pathway (Mehlhop and Diamond, 2006).
These ﬁndings were consistent with previous ﬁndings in which IgG
responses to a T-dependent antigen were normal in fB−/− mice
(Matsumoto et al., 1997) and indicated that components of the
alternative complement activation pathway are not required for the
development of an anti-WNV antibody response. In contrast,
components of the classical and lectin complement activation path-
ways, C4 and C1q, were required for normal humoral responses to
WNV infection (Mehlhop and Diamond, 2006). Interestingly, C4, but
not C1q, was required for normal anti-WNV IgM responses, whereas
both C4 and C1q were required for normal anti-WNV IgG responses.
These ﬁndings suggest that distinct complement pathways regulate
IgM vs. IgG responses, at least in the context of a viral infection.
Importantly, similar to C3 and CR2 deﬁcient mice, C4- and C1q-
deﬁcient mice were much more susceptible to lethal WNV-infection,
providing further evidence that the host's complement system is
critical to limit the severity of WNV disease (Mehlhop and Diamond,
2006).
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recent studies have identiﬁed a critical role for complement, and in
particular the complement component C1q, in the regulation of anti-
viral antibody effector mechanisms. Researchers investigating the
serum-speciﬁc enhancement of inﬂuenza virus hemagglutinin (HA)-
speciﬁc monoclonal antibodies discovered that C1q could enhance
both neutralization activity and hemagglutination inhibition (HI)
activity (Feng et al., 2002). C1q more strongly inﬂuenced HI activity,
and this enhancement did not require C3, suggesting that the effects
were independent of C1q-mediated complement activation. C1q-
mediated enhancement of HI activity and neutralizing activity was
dependent on the antibody isotype and epitope speciﬁcity (Feng et al.,
2002; Mozdzanowska et al., 2006).
Antibody-dependent enhancement (ADE) of infection has been
described for multiple viruses (Takada and Kawaoka, 2003). In the
case of dengue viruses, ADE is associated with more severe disease
(Balsitis et al., 2010; Kyle and Harris, 2008; Zellweger et al., 2010).
Utilizing in vitro assays designed to measure ADE of dengue virus
infection, researchers discovered that the presence of fresh serum
could completely abolish ADE (Mehlhop et al., 2007; Yamanaka et al.,
2008). Further analyses demonstrated that the inhibitory effect of
fresh serum on ADE was C1q-dependent and antibody isotype-
speciﬁc (Mehlhop et al., 2007; Yamanaka et al., 2008). However, in
separate studies the suppression of ADE by fresh serum was found to
be C3-dependent or C3-independent, thus the extent to which other
complement components participate in mediating these effects is
unclear. In addition to suppressing ADE, C1q was shown to enhance
the neutralizing activity of anti-WNV antibodies (Mehlhop et al.,
2009). Mechanistic studies revealed that C1q reduced the number of
antibodies required to bind a WNV virion and neutralize infectivity.
Interestingly, C1q reduced the number of antibodies required for
neutralization to levels below theminimum number required for ADE.
Importantly, the ability of an anti-WNV antibody to protect from
lethal infection was decreased in C1q−/−mice compared to wild-type
mice, indicating that C1q enhancement of neutralizing activity
regulates WNV pathogenesis. In contrast to the effect of C1q on ADE
of ﬂavivirus infection, ADE of Ebola Zaire virus infection is C1q-
dependent (Takada et al., 2003). The glycoprotein of the Reston strain
of Ebola virus, which is less pathogenic in humans, induces less
enhancing activity compared to the Zaire strain, suggesting that ADE
may also play a role in Ebola virus pathogenesis.
T cell immunity
Regulation of T cells by the complement system. Increasing evidence
from various experimental systems indicates that complement
regulates CD4+ and CD8+ T cell activation and effector functions
(Dunkelberger and Song, 2010; Kemper and Atkinson, 2007).
Numerous complement receptors and membrane complement regu-
latory proteins can be expressed by antigen-presenting cells (APCs)
and T cells. Engagement of these receptors on APCs regulates APC
effector functions, such as chemokine and cytokine gene expression,
and modulation of APC function inﬂuences T cell activation during
antigen presentation. Direct action of complement on T cells is less
well understood. Ligation of CR1 on T cells has been shown to inhibit T
cell proliferation (Wagner et al., 2006), while the C5a receptor (C5aR)
has been shown to regulate T cell trafﬁcking (Tsuji et al., 2000). In
addition, several membrane complement regulatory proteins have
been linked to T cell regulation. For example, CD46, which binds C3b
and C4b and serves as a cofactor for their proteolytic inactivation, was
found to regulate the proliferation and effector functions of CD4+ and
CD8+ T cells (Marie et al., 2002). Critically, complement regulates the
effector function of activated T cells by regulating the development of
Th1, Th2, and Th17 helper cells. For example, C3aR-deﬁcient mice
were protected against Th2-dependent airway hypereactivity and this
has been linked to both decreased Th2 cell responses and enhance-ment of IL-17 producing helper T cells (Drouin et al., 2001; Lajoie
et al., 2010). In contrast C5 provides protection against airway
hypereactivity by regulating Th17 cytokine production (Lajoie et al.,
2010). Finally, evidence suggests that complement also regulates the
termination of T cell responses by inducing the development of
regulatory T cells (Kemper et al., 2003).
Complement enhances T cell responses to viral infection. Utilizing
mouse models, researchers discovered that C3 was required for
normal T cell responses to inﬂuenza virus, lymphocytic choriomen-
ingitis virus (LCMV) infection, and Friend virus (FV) infection (Banki
et al., 2010; Kopf et al., 2002; Suresh et al., 2003). In vitro, dendritic
cells exposed to complement-opsonized FV or HIV were better
inducers of CD8+ T cell activation (Banki et al., 2010). These effects
were also observed with complement opsonized FV in mice.
Furthermore, C3-deﬁcient mice had reduced numbers of FV-speciﬁc
CD8+ T cells and higher numbers of infected spleen cells compared
to wild-type controls, suggesting complement-mediated regulation
of T cell responses functions to control FV replication (Banki et al.,
2010). Similarly, mice deﬁcient in C3 had delayed clearance of
inﬂuenza virus and increased titers in the lungs. These ﬁndings
correlated with a dramatic decrease in the recruitment of virus-
speciﬁc CD4+ and CD8+ T cells producing IFN-γ to the lung of
inﬂuenza virus-infected C3−/− mice. Following either LCMV or
inﬂuenza virus infection, C3 was required for normal priming of
CD4+ and CD8+ T cells and mice deﬁcient in CR1 and CR2 (CR2−/−
mice) did not show any of these defects, indicating that C3
regulates T cell responses in a CR1/CR2-independent manner
(Kopf et al., 2002; Suresh et al., 2003). In LCMV-infected mice, the
effects of C3 on CD8+ T cell priming and expansion were epitope-
dependent and inﬂuenced by the mouse genetic background,
suggesting that C3 may regulate epitope selection. Subsequent
experiments indicated that the C5aR may have an important role in
the regulation of T cell responses to inﬂuenza virus infection as
treatment of mice with a C5aR antagonist reduced the number of
inﬂuenza virus-speciﬁc CD8+ T cells in both the lungs and lymphoid
tissue (Kim et al., 2004).
Studies utilizing a mouse model of WNV infection and disease
identiﬁed distinct complement pathways that regulate antiviral T cell
responses (Mehlhop and Diamond, 2006). Mice deﬁcient in fB were
found to be highly susceptible to lethalWNV infection, despite normal
anti-WNV antibody responses. Instead, fB−/− mice, but not C1q−/−
mice, had reduced CD8+ T cell responses in the spleen and impaired
trafﬁcking of CD4+ and CD8+ T cells to the CNS. Similar ﬁndings were
observed in WNV-inoculated C4−/− mice, suggesting that both the
lectin and alternative complement activation pathways contribute to
regulation of T cell functions. Thus, similar to FV, inﬂuenza virus, and
LCMV infections, complement activation was required for normal
T cell priming and trafﬁcking following WNV infection.
The role of complement regulatory proteins in regulating T cell
responses to viral infection has also been investigated. Mice deﬁcient
in decay accelerating factor (DAF; CD55), which regulates formation
and inactivation of the C3 and C5 convertases, had an increased
expansion of CD8+ T cellswith greater killing capacity following LCMV
infection and this correlated with lower viral titers. These enhanced
CD8+ T cell responses were reversed in mice deﬁcient for DAF and C3
(Daf-1−/−; C3−/−) or DAF and the C5aR (Daf-1−/−; C5aR−/−). In
contrast, following vaccinia virus infection, CD4+, but not CD8+, T cell
responses were enhanced in mice deﬁcient in CD59a, which blocks
formation of the membrane attack complex (Longhi et al., 2005).
Taken together, these studies suggest that membrane complement
regulators regulate both CD4+ and CD8+ T cell immunity. However,
CD4+ T cell responses following vaccinia virus infection were
enhanced in both CD59a−/− and CD59a−/−; C3−/− mice, indicating
that the effects of CD59a on T cell responseswere likely independent of
complement activation, at least following vaccinia virus infection.
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Complement and diseases associated with hepatitis C virus infection
Hepatitis C virus (HCV) appears to exploit the complement system
to establish persistence. HCV core protein is the ﬁrst protein
expressed during the early phase of HCV infection and free HCV
core particles are found in the blood of HCV-infected patients
(Maillard et al., 2001). By evaluating various vaccinia virus (VV)/
HCV recombinants in mice, Large et al. discovered that a recombinant
VV expressing the HCV core protein produced a lethal infection in
mice and suppressed the VV-speciﬁc CD8+ T cell response (Large
et al., 1999). Using a yeast two-hybrid approach, Kittlesen and
colleagues identiﬁed that the HCV core protein bound the gC1q
receptor (gC1qR) speciﬁc for the globular heads of the C1q protein
(Kittlesen et al., 2000) (Fig. 3). Binding of gC1qR by the HCV core
protein inhibited human peripheral blood T cell proliferation in
standard one-way mixed lymphocyte reactions (MLR) or following
mitogen stimulation (Kittlesen et al., 2000), a similar effect to the
binding of C1q, the natural ligand for the gC1qR. This suppression was
reversed by the addition of anti-gC1qR or anti-core antibodies in the
T-cell proliferation assay (Kittlesen et al., 2000). More speciﬁcally,
binding of HCV core protein to gC1qR on activated human peripheral
blood T cells decreased IL-2 and IFN-γ production and decreased IL-2R
and CD69 expression (Yao et al., 2001). A recent clinical study
investigated the impact of HCV infection on T cell responses in acute
as compared to resolved versus chronic infection (Cummings et al.,
2009). During the acute phase of HCV infection, the frequency of
gC1qR+CD4+ T cells increased compared to healthy controls. Six
months later, the frequency of gC1qR+CD4+ T cells remained elevated
in chronic patients compared to that in resolved patients. Chronic
patients also had higher levels of circulating HCV core protein. TCR
stimulation increased the frequency of gC1qR+CD4+ T cells, resulting
in core-induced inhibition of T cell responses in both resolved and
chronic patients. These results suggest that HCV infection expands
gC1qR+CD4+ T cells, increasing the susceptibility to core-mediated
immune dysregulation (Cummings et al., 2009).
The gC1qR is also expressed by other immune cells, such as
dendritic cells (DCs) and B cells. DCs isolated from patients chronically
infected with HCV display a reduced capacity to induce T cell
activation and to produce Th1 cytokines (Auffermann-Gretzinger et
al., 2001; Bain et al., 2001; Dolganiuc et al., 2003; Kakumu et al., 2000;
Kanto et al., 1999, 2004).Waggoner and colleagues demonstrated that
binding of the HCV core protein to gC1qR on human monocyte-
derived DCs (MDDCs) inhibited TLR-induced IL-12 production but not
the production of other TLR-induced cytokines (Waggoner et al.,
2007). In addition, HCV core protein engagement of gC1qR on MDDCs
promoted the production of Th2 cytokines such as IL-4 by cocultured
CD4+ T cells. These results suggest that engagement of gC1qR on DCs
by HCV core limits the induction of Th1 responses (Waggoner et al.,
2007). In contrast to the effects on T cells and DCs, HCV core protein
binding to gC1qR on B cells leads to B cell activation and proliferation:
increased costimulatory and chemokine receptor expression, cell
proliferation, IgM and IgG production, and STAT1 phosphorylation,
and down-regulation of SOCS-1 expression (Yao et al., 2008). These
data suggest that HCV exploits the complement system to dysregulate
the host immune response via various mechanisms in order to
establish persistence. To further investigate the role of the HCV core
protein in HCV pathogenesis, transgenic mice were developed with
tetracycline-regulated conditional HCV core protein expression
(Chang et al., 2009). These mice develop liver inﬂammation, steatosis,
and ﬁbrosis. Microarray analyses of inﬂamed liver showed induction
of many components of both the complement and coagulation
pathways, and administration of CD55 (DAF) decreased hepatic
inﬂammation, suggesting that the HCV core and the complement
system contribute to hepatic inﬂammation associated with HCV
infection.Cryoglobulinemia is a systemic vasculitis that damages small and
medium-sized arteries and veins of the skin, kidneys, and peripheral
nerves (Dammacco et al., 2001), and evidence suggests that the
deposition of immune complexes on the vessel wall activates
complement and mediates this damage. Mixed cryoglobulinemia
(MC), which involves multiple immunoglobulin isotypes, is observed
in 10–70% of hepatitis C virus (HCV)-infected patients and is
associated with increased duration of HCV infection (Charles and
Dustin, 2009). In HCV-positive patients with MC, circulating, none-
nveloped HCV core protein was detected in cryoprecipitable immune
complexes (Sansonno et al., 2003). As discussed above, the HCV core
protein interacts with the gC1qR. The gC1qR can be proteolytically
cleaved and released from the cell surface (Kittlesen et al., 2000).
Studies with HCV-positive MC patients revealed that MC following
HCV infection correlated with signiﬁcantly higher levels of circulating
gC1qR compared to HCV-infected patients without MC (Sansonno
et al., 2009). In addition, higher serum gC1qR levels negatively
correlated with circulating levels of the C4d fragment, which was
instead sequestered in the vascular bed from skin biopsies of MC
patients, indicative of complement activation in the vascular bed
(Sansonno et al., 2009). These data suggest that following HCV
infection, dysregulated shedding of gC1qR molecules contributes to
vascular cryoglobulin-induced damage via a complement-mediated
pathway (Sansonno et al., 2009). HCV has also been linked to
pulmonary diseases such as asthma and chronic obstructive pulmo-
nary disease (COPD) (Moorman et al., 2005a). In in vitro studies using
normal human lung ﬁbroblasts, Moorman and colleagues found that
the HCV core protein induced IL-8 mRNA and protein expression via
gC1qR (Moorman et al., 2005b). Taken together, these studies suggest
that the HCV core protein interaction with the gC1q receptor of the
complement system contributes to the pathogenesis of multiple
diseases associated with HCV infection. Further investigation into the
proinﬂammatory role of the HCV core protein may provide a clearer
understanding of the pathogenesis of HCV-associated diseases.
Chronic HCV infection is characterized by persistent complement
activation, and can lead to liver ﬁbrosis despite antiviral therapies. By
interbreeding ﬁbrosis-susceptible and ﬁbrosis-resistant strains of
mice, C5 was identiﬁed to be associated with hepatic ﬁbrosis, and
small molecule inhibitors of the C5a receptor had antiﬁbrotic effects
in vivo (Hillebrandt et al., 2002). Polymorphisms of the human gene
C5 were associated with advanced liver ﬁbrosis, as compared with
mild ﬁbrosis, in chronic HCV infection (Hillebrandt et al., 2005)
(Fig. 3). Moreover, the at-risk C5 haplotype in humans was associated
with high serum C5 levels (Hillebrandt et al., 2005). These data
suggest that C5 has a causal role in non-HCV and HCV-associated
hepatic ﬁbrosis across species and that C5-targeted therapeutics could
be a beneﬁcial treatment strategy.
Complement and dengue virus-induced disease
Although DENV NS1 can inhibit activation of the complement
system (Avirutnan et al., 2010), evidence suggests that complement
activation may contribute to increased disease severity following
DENV infection (Fig. 3). Dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS) are serious clinical conditions that typically
occur after a second dengue infection by a different viral serotype or
after a primary infection in infants born to dengue-immune mothers.
Lower levels of C3, C4, and fB, and higher levels of C3 cleavage
products, were detected in severely ill DHF patients and correlated
with signs of shock, suggesting that complement activation con-
tributes to the more severe forms of dengue virus-induced disease
(Bokisch et al., 1973; Churdboonchart et al., 1983; Nascimento et al.,
2009). In addition, DHF patients have been found to have higher levels
of fD, which cleaves fB to yield the active (C3bBb) C3 convertase, and
lower levels of fH, which inactivates the (C3bBb) C3 convertase,
compared to patients with DF (Nascimento et al., 2009). Other studies
have shown that plasma levels of sNS1 and products of complement
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C5a, and the terminal SC5b-9 complement complex, were present at
higher levels in DHF patients before plasma leakage took place
(Avirutnan et al., 2006), further supporting the hypothesis that
complement activation is involved in the development of severe
disease. Comparison of global gene expression proﬁles in peripheral
blood mononuclear cells (PBMCs) of patients with DF or DHF
discovered that the complement inhibitor CD59 was more strongly
up-regulated in PBMCs from DF patients than in PBMCs from DHF
patients. Furthermore, the wild-type MBL genotype, but not MBL
genotypes associated with reduced MBL levels, was associated with
the development of dengue-related thrombocytopenia and more
severe disease (Acioli-Santos et al., 2008). This is interesting given the
recent ﬁndings that MBL binds DENV resulting in complement
activation and virus neutralization (Fuchs et al., 2010). These studies
implicate the complement system in the pathogenesis of the more
severe forms of dengue virus associated disease, DHF/DSS; however,
the mechanisms by which the complement system contributes to
disease severity are not well understood.Complement and alphavirus-induced rheumatic disease
Arthritogenic alphaviruses, including Ross River virus (RRV) and
chikungunya virus, are mosquito-borne viruses that cause debilitating
musculoskeletal inﬂammation and pain in humans. Evidence of
complement activation was detected in synovial ﬂuid from RRV-
infected patients (Morrison et al., 2007). Similarly, in a mouse model
of RRV-induced disease, complement activation products were
detected in inﬂamed joint and muscle tissues of wild-type mice
(Morrison et al., 2007). RRV-infected C3-deﬁcient mice exhibited less
severe destruction of skeletal muscle tissue and less severe disease
signs, indicating an important role for complement in RRV pathogen-
esis (Fig. 3). Mice deﬁcient in CR3 (CD11b−/−) also developed less
severe tissue damage and disease signs following RRV infection
(Morrison et al., 2008) (Fig. 3). Interestingly, neither C3 nor CR3
deﬁciency prevented recruitment of inﬂammatory leukocytes to
musculoskeletal tissues, suggesting that C3 and CR3 may act
downstream of inﬂammatory cell invasion to promote tissue damage
during RRV infection (Morrison et al., 2007, 2008). The genetic
absence of C3 and CR3 signiﬁcantly diminished RRV-induced
expression of S100A9, S100A8, and IL-6 within inﬂamed skeletal
muscle tissue, indicating that the induction was regulated, at least in
part, by CR3 interaction with its C3-derived ligand iC3b (Morrison
et al., 2008). Furthermore, mice deﬁcient in MBL (MBL-DKO) also
developed less severe RRV-induced disease and these mice had
reduced MBL and C3 deposition on tissues (unpublished results),
providing evidence that RRV infection leads to complement activation
via the lectin-dependent activation pathway. Taken together, these
studies suggest that interfering with the complement cascade and/or
complement receptor signaling may represent a useful route for
therapeutic intervention of RRV-induced disease.Complement and virus-induced seizures
Finally, recent evidence suggests that the complement systemmay
contribute to seizures induced by virus infection. Infection of wild-
type mice with Theiler's murine encephalomyelitis virus (TMEV)
results in acute seizures (Libbey et al., 2008, 2010). In contrast, C3−/−
mice developed far fewer seizures following TMEV infection which
correlated with reduced numbers of activated microglia and macro-
phages in the hippocampus and dentate gyrus as well as decreased
neuronal cell loss (Libbey et al., 2010) (Fig. 3). Interestingly, depletion
of systemic complement with cobra venom factor did not impact
TMEV-induced seizures, suggesting that locally produced comple-
ment within the central nervous system is sufﬁcient to enhance
TMEV-induced seizures (Libbey et al., 2010).Conclusions
It is clear that the complement system is a critical determinant of
the outcome of infection by a variety of different viruses. Our
understanding of the mechanisms by which complement protects
from virus-induced disease has improved dramatically. Research in
this areawill not only continue to contribute to our knowledge of viral
pathogenesis, but will continue to provide insight into the regulation
of immune responses, and lead to improved therapeutic and vaccine
approaches for both viral and non-viral pathogens. Perhaps less well
understood are the mechanisms by which complement functions as a
pathogenic effector in some virus-induced diseases. Further progress
towards identifying the signals and pathways that lead to complement
activation, which are not understood for many viruses, particularly in
vivo, and a deeper understanding of the impact of complement
activation on host immune responses to viral infectionmay shed light.
For example, recent studies have identiﬁed critical roles for the
complement system in the regulation of Th17 cells (Lajoie et al., 2010),
regulation of myeloid-derived suppressor cells (Markiewski et al.,
2008), and the induction of autophagy (Joubert et al., 2009), all of
which have been linked to virus-induced disease. In addition, the
complement system is intricately linkedwith other pathways that play
important roles in viral pathogenesis, such as the Toll-like receptor
signaling network and the coagulation system (Hajishengallis and
Lambris, 2010; Markiewski et al., 2007). Thus, continued investigation
of the role of complement in viral pathogenesis will provide important
insights into virus–host interactions and strategies to prevent or treat
virus-induced disease.Acknowledgments
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